Verified reporting on patents, licensing, invention commercialisation, intellectual-property policy and the disputes that shape who can build what comes next. Updated daily.
The agreement ends identified pending litigation and licenses Netlist's worldwide portfolio, including server-DIMM and high-bandwidth-memory patents. The $600 million will be paid quarterly, not as a lump sum.
Read story
The multi-year agreement covers 5G, computing, AI and networking portfolios and includes Qualcomm’s purchase of selected Huawei U.S. patents. Financial terms, portfolio lists and royalty mechanics remain undisclosed.
Read story
A Delaware jury will hear Qualcomm’s claims that Arm withheld contractually required tools and publicized a termination threat. Arm denies wrongdoing, and the court has not decided whether Qualcomm can suspend royalties for up to five years.
Read story
Novartis will pay $575 million upfront for worldwide rights to ABO2203 and options on other Abogen RNA programs. The much larger headline figure depends on development, approvals and commercialization that may never occur.
Read story
A Delaware judge ruled that the federal government’s license to university inventions does not automatically protect a private supplier. Moderna’s separate government-contract defense—and the underlying infringement claims—remain unresolved.
Read story
A Delaware lawsuit adds JA Solar companies and American Panel Solutions to a growing dispute over a manufacturing patent for high-efficiency crystalline-silicon cells. The filing could test how broadly one of solar's most commercially important process portfolios reaches.
Read story
The multi-year agreement gives Amazon broader access to application-optimized silicon blueprints while shifting Synopsys toward a license-plus-royalty model. It is a major test of how reusable chip IP will shape the custom-silicon race.
Read story
The first U.S. appellate result in an AI-training copyright dispute leaves Ross Intelligence's fair-use defense rejected, but the sealed opinion makes sweeping conclusions premature.
Read story
A Delaware judge refused to dismiss Bayer and Monsanto’s patent suits against Moderna, Pfizer and BioNTech. The ruling keeps the cases alive, but does not establish infringement or finally settle the patent’s validity.
Read story